Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) agreed to pay for $7.2 billion in stock and money for Marijuana Derived Epilepsy Drug – Epidiolex produced by GW Pharmaceuticals Plc (NASDAQ: GWPH). The offer will likely to be closed in Q2.
As per the pact terms, GW Pharmaceuticals investors will get american shares that are depositary each at $220. The deal includes Jazz stock worth $20 and cash of $200 for each share.
Cures rare forms of the disease
GW Pharmaceuticals Epilepsy drug – Epidiolex, which is based on marijuana, is used to treat rare forms of the disease. According to a communiqué from the companies on Epilepsy drug garnered $510 million in 2020 wednesday. GW Pharmaceuticals accumulated $32,500 from each client as annualized fee within the US in 2018.
Strengthens neuroscience medication pipeline
Jazz strengthens its neuroscience medication pipeline through this deal. Bruce Cozadd, CEO of Jazz, stated Epidiolex expects to build yearly product sales of $1 billion quickly. The cannabinoid-based medications of GW Pharmaceuticals are tested to deal with schizophrenia, autism, as well as other conditions that are medical
Jazz, which is based in Dublin, engages in the manufacture of drugs to treat diseases that are rare. These medications produced product sales of $1.7 billion in Q3 2020 (up 7.5% YoY). Xyrem, its best-selling medication, really helps to cure narcolepsy.
Following the offer, Jazz’s stocks declined by 5.1per cent on Wednesday on issues that the organization will pay an increased premium to analysts quotes of GW pharmaceuticals performance that is financial. An SVB Leerink LLC analyst, Ami Fadia, said the pact is a fit that is strategic Jazz, which centers around neuroscience.
With this deal, Jazz included products that are cannabinoid-based its product line. It is an move that is aggressive Jazz to takeover GW Pharmaceuticals at an increased cost. The shares of GW Pharmaceuticals trade higher at $214.77 (up 46.85%) on March 2, 2021, whereas Jazz, is also rebounding.
Jazz posted revenues of $665 million (up 14.4% YoY) in Q4 2020, exceeding the analysts’ forecasts. The company expects to post sales of $2.7 billion in 2021 as per analysts’ estimates. Jazz offers treatments for indications in hematology-oncology, indications in neuroscience, and sleep disorders. Its drug that is promising Zepzelca a cure for little lung cancer tumors.